David Bearss, Ph.D., is the co-founder and President of Biolexis Therapeutics. This innovative biotechnology company leverages AI-driven drug discovery to advance groundbreaking therapies targeting metabolic disorders. With a distinguished career as a scientist and entrepreneur, Dr. Bearss has successfully translated cutting-edge research into impactful clinical therapies, resulting in numerous patents and high-impact publications. Dr. Bearss previously founded and led multiple biotechnology ventures, including Halia Therapeutics and Tolero Pharmaceuticals (acquired by Sumitomo Dainippon Pharma), demonstrating consistent expertise in driving drug development from discovery to clinical validation. Under his leadership, Biolexis has pioneered the Moleculern AI platform, enabling the discovery of novel allosteric modulators of GLP-1 and isoform-specific AMPK activators, now advancing into clinical development for obesity, diabetes, and related metabolic diseases. A respected figure in biotechnology innovation, Dr. Bearss is committed to collaborative scientific advancement and regularly speaks at international conferences, advocating for strategic partnerships that accelerate therapeutic breakthroughs. He holds a Ph.D. in Cell and Molecular Biology from the University of Texas Health and continues to influence the biotech landscape through visionary leadership and transformative science.